New EU Approvals
The Pink Sheet’s list of EU centralized approvals of new active substances now includes two new products, one of which is bluebird bio's genetically modified product for treating beta-thalassemia, Zynteglo. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).
You may also be interested in...
Health technology assessment body NICE is consulting on draft guidance that recommends Axonics' device for overactive bladder.
The risk of developing meningioma with cyproterone-containing medicines is rare, but it is serious enough to merit restrictions on how such products are used, according to the European Medicines Agency.
The European Medicines Agency has agreed to review pan-EU marketing applications for a number of new medicines.